Ns Pharma, Inc.
Clinical trials sponsored by Ns Pharma, Inc., explained in plain language.
-
New hope for duchenne: experimental drug aims to restore muscle protein
Disease control OngoingThis early-stage trial is testing a drug called NS-050/NCNP-03 in 20 boys with Duchenne muscular dystrophy (DMD) who have a specific genetic mutation. The drug is designed to skip a faulty section of the dystrophin gene, allowing the body to produce a shorter but still functional…
Phase: PHASE1, PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare disease: can NS-229 help patients reduce steroids?
Disease control OngoingThis study tests a new medicine, NS-229, in 45 adults with a rare disease called eosinophilic granulomatosis with polyangiitis (EGPA), which causes inflammation in blood vessels. The goal is to see if NS-229 can help patients achieve remission while lowering their daily steroid d…
Phase: PHASE2 • Sponsor: NS Pharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC